Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
VRTX logo

Vertex Revenues Rise 3% to $2.8B on CF Strength, But Net Income Drops 41% Amid R&D Surge

VRTX10-QFiling Date: 5/6/2025
Vertex Pharmaceuticals Incorporated
Description

What this story covers

Vertex's Q1 2025 10-Q reveals $2.8B revenues up 3% driven by cystic fibrosis drugs, with new launches like Alyftrek adding momentum. Net income fell 41% to $646M due to $980M R&D investments and a $379M impairment. Pipeline advances in pain, diabetes, and kidneys, backed by $11.4B cash for diversification.

Story snapshot

CompanyVertex Pharmaceuticals Incorporated
TickerVRTX
VariantStandard detailed
Duration11:47
Filing type10-Q
PeriodQ1 2025
IndustryHealthcare & Pharmaceuticals
Accession0000875320-25-000192

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in